The FDA has cleared Allogene Therapeutics' IND application for ALLO-329, a novel dual-targeting CAR T cell therapy designed to treat multiple...

Researchers have engineered a minimal type I-F2 CRISPR-Cas system capable of transcriptional activation and base editing in human cells. This...

In this update, we highlight recent news on Poseida Therapeutics' fully allogeneic CAR-T candidate for multiple myeloma (P-BCMA-ALLO1), Intellia's and...

Researchers in the US have demonstrated that a single local injection of lentiviral particles carrying Cas9 and a MYOC-targeting gRNA reverses disease...

A team based at University of California and Sanford Consortium for Regenerative Medicine report that gene editing can rescue mitochondrial defects...

Fate Therapeutics announced this week that enrolment is underway for a Phase 1 trial of FT-825/OMO-8250 in advanced HER2-expressing solid tumours.

As 2023 draws to a close, we look back on some of the major clinical highlights from the year gone by.

In this article, we look at recent clinical updates from the gene-editing field. These updates include clinical data from Vor Bio's ongoing Phase 1/2a...